Aims and objectives
Non–small cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer cases .
Since its introduction in clinical practice,
immunotherapy revolutionized the treatment of NSCLC but nowadays there are no reliable clinical or biological markers that can predict response to immune checkpoint inhibitors.
Expression of Programmed-Death Ligand 1 (PD-L1) is considered unreliable to predict response to therapy due to intratumoral heterogeneous expression and non-standardized techniques...
Methods and materials
Patient Selection We retrospectively evaluated baseline contrast-enhanced CT scans of 23 patients with Stage IIIb/IV NSCLC who were treated with a PD-1 Immune checkpoint Inhibitor (Nivolumab) from January 2015 to May 2017 at San Martino Policlinic,
University of Genoa.
All Patients received multiple lines of conventional chemotherapy and/or radiotherapy without clinical benefit before immunotherapy. CT acquisition,
Reconstruction and Segmentation CT scan data were acquired using the following...
The accuracy of our models was 60% (AUC 0,60) for unfiltered images and 91,3% (AUC 0,92) (Fig.2),
56,5% (AUC 0,56) and 56,5% (AUC 0,59) for images filtered respectively with low (filter 1.0),
medium (filter 2.0) and high (filter 3.0) values.
Tang et Al  elaborated a radiomic signature that correlated with tumor immune microenvironment.
Our study lacks a pathological correlation but our predictive model can identify a specific radiological phenotype that is associated with a better OSin patients treated with immunotherapy for NSCLC.
Only the model with CT images filtered with a low value performed well in distinguish patients with increased OS: probably these parameters permit to markedly decrease noise,
a factor that could...
 Govindan R,
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance,
and end results database.
J Clin Oncol 2006; 24:4539–44.  El Naqa I,
Ten Haken RK Can radiomics personalise immunotherapy? Lancet Oncol.
2018 Sep;19(9):1138-1139.  McLaughlin J,
Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA...